Phase 2b Controlled Trial of M72/AS01
Date
2018-Oct-25
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: A vaccine to interrupt the transmission of tuberculosis is needed.
METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01
RESULTS: We report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial. A total of 1786 participants received M72/AS01
CONCLUSIONS: M72/AS01